Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Graft-Versus-Host Disease | Case report

A misdiagnosed case of blastic plasmacytoid dendritic cell neoplasm experiencing multiple recurrences who underwent allogeneic stem cell transplantation: a case report

Authors: Fateme Salemi, Seyed Mohammad Reza Mortazavizadeh, Seyyedmohammadsadeq Mirmoeeni, Amirhossein Azari Jafari, Farid Kosari, Seyed Sina Naghibi Irvani

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Background

Blastic plasmacytoid dendritic cell neoplasm represents a rare type of hematologic malignancy that often manifests itself through various skin lesions. It commonly affects the elderly male population. Lymph nodes, peripheral blood, and bone marrow involvement are the typical findings that justify its aggressive nature and dismal prognosis. On histopathological assessment, malignant cells share some similarities with blastic cells from the myeloid lineage that make immunohistochemistry staining mandatory for blastic plasmacytoid dendritic cell neoplasm diagnosis.

Case presentation

A 35-year-old Asian man presented with cervical lymphadenopathy followed by an erythematous lesion on his left upper back. At first, the lesion was misdiagnosed as an infectious disease and made the patient receive two ineffective courses of azithromycin and clarithromycin. Six months later, besides persistent skin manifestations, he felt a cervical mass, which was misdiagnosed as follicular center cell lymphoma. Tumor recurrence following the chemoradiation questioned the diagnosis, and further pathologic assessments confirmed blastic plasmacytoid dendritic cell neoplasm. The second recurrence occurred 3 months after chemotherapy. Eventually, he received a bone marrow transplant after complete remission. However, the patient expired 3 months after transplant owing to the third recurrence and gastrointestinal graft versus host disease complications.

Conclusions

Early clinical suspicion and true pathologic diagnosis play a crucial role in patients’ prognosis. Moreover, allogenic bone marrow transplant should be performed with more caution in aggressive forms of blastic plasmacytoid dendritic cell neoplasm because of transplant side effects and high risk of cancer recurrence.
Literature
1.
go back to reference Yang CL, Zhao S, Wang L, Zou LQ. Blastic plasmacytoid dendritic cell neoplasm: a case report. Acta Derm Venereol. 2019;99(4):456–7.CrossRef Yang CL, Zhao S, Wang L, Zou LQ. Blastic plasmacytoid dendritic cell neoplasm: a case report. Acta Derm Venereol. 2019;99(4):456–7.CrossRef
2.
go back to reference Wang T, Liu L, Zhang RY, Guo J. Lymph blastic plasmacytoid dendritic cell neoplasm: a case report and review of literature. Int J Clin Exp Med. 2019;12(1):1127–31. Wang T, Liu L, Zhang RY, Guo J. Lymph blastic plasmacytoid dendritic cell neoplasm: a case report and review of literature. Int J Clin Exp Med. 2019;12(1):1127–31.
3.
go back to reference World Health Organization. WHO Classification of tumours of haematopoietic and lymphoid tissues, Fourth Edition. 2008. World Health Organization. WHO Classification of tumours of haematopoietic and lymphoid tissues, Fourth Edition. 2008.
4.
go back to reference Mansour Y, Stadler R. Blastic plasmacytoid dendritic cell neoplasm, a rare hematological manifestation of the skin. JDDG. 2019;17:61.CrossRef Mansour Y, Stadler R. Blastic plasmacytoid dendritic cell neoplasm, a rare hematological manifestation of the skin. JDDG. 2019;17:61.CrossRef
5.
go back to reference Szablewski V, Costes V, Bret C, Dereure O, Yosr H, Alame M, et al. Cutaneous presentation preceding acute myeloid leukemia with CD4+/CD56+expression misdiagnosed as a blastic plasmocytoid dendritic cell neoplasm: a case report. J Cutan Pathol. 2018;45(8):610–4.CrossRef Szablewski V, Costes V, Bret C, Dereure O, Yosr H, Alame M, et al. Cutaneous presentation preceding acute myeloid leukemia with CD4+/CD56+expression misdiagnosed as a blastic plasmocytoid dendritic cell neoplasm: a case report. J Cutan Pathol. 2018;45(8):610–4.CrossRef
6.
go back to reference Owczarczyk-Saczonek A, Sokolowska-Wojdylo M, Olszewska B, Malek M, Znajewska-Pander A, Kowalczyk A, et al. Clinicopathologic retrospective analysis of blastic plasmacytoid dendritic cell neoplasms. Postepy Dermatologii I Alergologii. 2018;35(2):128–38.CrossRef Owczarczyk-Saczonek A, Sokolowska-Wojdylo M, Olszewska B, Malek M, Znajewska-Pander A, Kowalczyk A, et al. Clinicopathologic retrospective analysis of blastic plasmacytoid dendritic cell neoplasms. Postepy Dermatologii I Alergologii. 2018;35(2):128–38.CrossRef
8.
go back to reference Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74–9.CrossRef Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74–9.CrossRef
10.
go back to reference McDonald GB. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood. 2016;127(12):1544–50.CrossRef McDonald GB. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood. 2016;127(12):1544–50.CrossRef
12.
go back to reference Xin X, Tian M, Huang LF, Wang GX, Cheng L, Liu ZJ, et al. Cutaneous lesions from a blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Int J Clin Exp Med. 2016;9(2):5017–22. Xin X, Tian M, Huang LF, Wang GX, Cheng L, Liu ZJ, et al. Cutaneous lesions from a blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Int J Clin Exp Med. 2016;9(2):5017–22.
13.
go back to reference Barros Romao C, Santos Junior CJD, Leite LAC, Gomes Alves MJR, Araujo NS, Castro AFL, et al. Blastic plasmacytoid dendritic cell neoplasm with pulmonary involvement and atypical skin lesion. Am J Case Rep. 2017;18:692–5.CrossRef Barros Romao C, Santos Junior CJD, Leite LAC, Gomes Alves MJR, Araujo NS, Castro AFL, et al. Blastic plasmacytoid dendritic cell neoplasm with pulmonary involvement and atypical skin lesion. Am J Case Rep. 2017;18:692–5.CrossRef
15.
go back to reference Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Miura K, et al. Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature. Int J Clin Exp Med. 2015;8(5):8204–9.PubMedPubMedCentral Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Miura K, et al. Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature. Int J Clin Exp Med. 2015;8(5):8204–9.PubMedPubMedCentral
16.
go back to reference Hamadeh F, Awadallah A, Meyerson HJ, Beck RC. Flow cytometry identifies a spectrum of maturation in myeloid neoplasms having plasmacytoid dendritic cell differentiation. Cytom Part B-Clin Cytom. 2020;98(1):43–51.CrossRef Hamadeh F, Awadallah A, Meyerson HJ, Beck RC. Flow cytometry identifies a spectrum of maturation in myeloid neoplasms having plasmacytoid dendritic cell differentiation. Cytom Part B-Clin Cytom. 2020;98(1):43–51.CrossRef
17.
go back to reference Pennisi M, Cesana C, Cittone MG, Bandiera L, Scarpati B, Mancini V, et al. A case of blastic plasmacytoid dendritic cell neoplasm extensively studied by flow cytometry and immunohistochemistry. Case Rep Hematol. 2017;2017:1–6.CrossRef Pennisi M, Cesana C, Cittone MG, Bandiera L, Scarpati B, Mancini V, et al. A case of blastic plasmacytoid dendritic cell neoplasm extensively studied by flow cytometry and immunohistochemistry. Case Rep Hematol. 2017;2017:1–6.CrossRef
18.
go back to reference Hwang K, Park CJ, Chi HS, Jang S, Park SJ, Huh JR, et al. Immunohistochemistry (CD123, CD56 AND CD4) reveals minimal bone marrow involvement in cases of blastic plasmacytoid dendritic cell neoplasm. Haematologica Hematol J. 2009;94:547–8. Hwang K, Park CJ, Chi HS, Jang S, Park SJ, Huh JR, et al. Immunohistochemistry (CD123, CD56 AND CD4) reveals minimal bone marrow involvement in cases of blastic plasmacytoid dendritic cell neoplasm. Haematologica Hematol J. 2009;94:547–8.
19.
go back to reference Cesarman-Maus G, Lome C, Espinosa KA, Quezada-Fiallos CM, Rivas S, Quezda R. Clinical and pathological features and differential diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN): a series of cases. Blood. 2016;128(22):5183.CrossRef Cesarman-Maus G, Lome C, Espinosa KA, Quezada-Fiallos CM, Rivas S, Quezda R. Clinical and pathological features and differential diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN): a series of cases. Blood. 2016;128(22):5183.CrossRef
20.
go back to reference Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer. 2017;7:85–93.CrossRef Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer. 2017;7:85–93.CrossRef
21.
go back to reference Pemmaraju N. Treatment advances in blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2019;17(4):207–9.PubMed Pemmaraju N. Treatment advances in blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2019;17(4):207–9.PubMed
22.
go back to reference Economides MP, McCue D, Lane AA, Pemmaraju N. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019;12(10):941–6.CrossRef Economides MP, McCue D, Lane AA, Pemmaraju N. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019;12(10):941–6.CrossRef
23.
go back to reference Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–92.CrossRef Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–92.CrossRef
24.
go back to reference Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–37.CrossRef Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–37.CrossRef
25.
go back to reference Alfayez M, Konopleva M, Pemmaraju N. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Biol Ther. 2020;20(2):115–23.CrossRef Alfayez M, Konopleva M, Pemmaraju N. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Biol Ther. 2020;20(2):115–23.CrossRef
26.
go back to reference Qazilbash MH, Ramdial J, Bashir Q, Milton DR, Patel RD, Popat UR, et al. Outcomes of allogeneic hematopoietic stem cell transplantation for BPDCN. Biol Blood Marrow Transplant. 2020;26(3):S106–7.CrossRef Qazilbash MH, Ramdial J, Bashir Q, Milton DR, Patel RD, Popat UR, et al. Outcomes of allogeneic hematopoietic stem cell transplantation for BPDCN. Biol Blood Marrow Transplant. 2020;26(3):S106–7.CrossRef
Metadata
Title
A misdiagnosed case of blastic plasmacytoid dendritic cell neoplasm experiencing multiple recurrences who underwent allogeneic stem cell transplantation: a case report
Authors
Fateme Salemi
Seyed Mohammad Reza Mortazavizadeh
Seyyedmohammadsadeq Mirmoeeni
Amirhossein Azari Jafari
Farid Kosari
Seyed Sina Naghibi Irvani
Publication date
01-12-2021

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue